Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Lanreotide (Somatuline): How the Somatostatin Copy Works

Lanreotide is a prescription drug that mimics somatostatin, a natural brake on many hormones, and it is sold in the US as Somatuline Depot. It is approved for acromegaly, for certain advanced gut and pancreas tumors, and for carcinoid syndrome.

The puzzle is time. Somatostatin is half gone from the blood in 1 to 3 minutes, but lanreotide takes 23 to 30 days to fall by half. Its FDA label says the drug is thought to form a slow-leaking store, or depot, once it meets body fluids. This page explains that depot, the receptors lanreotide grips, what the CLARINET tumor trial found, and where its approval stood on 20 November 2026.

On this page

Key facts

What it is: A lab-made ring of 8 amino acids that acts much like somatostatin, slowing the release of many hormones.

How long it lasts: A half-life of 23 to 30 days on the label, from a depot the drug is thought to form in the body.

Its main targets: Somatostatin receptors 2 and 5, which the label links to its hold on growth hormone.

Its best-known trial: CLARINET, 204 adults with advanced neuroendocrine tumors, where it delayed tumor growth or death on average.

Status on 20 November 2026: Somatuline Depot is a US prescription drug for acromegaly, certain GEP-NETs and carcinoid syndrome, and an Amneal generic was approved in September 2026.

Sources: Somatuline Depot label via openFDA, version 16; Caplin and colleagues, CLARINET, NEJM 2014; Drugs@FDA lanreotide records via openFDA

What is lanreotide?

Lanreotide is a somatostatin analog. Its label describes it as a synthetic cyclical octapeptide, which in plain words is a lab-made ring of 8 amino acids. A bond between two sulfur atoms closes the ring. The chain opens with an unusual block called 3-(2-naphthyl)-D-alanine and also holds D-tryptophan. The label gives a molecular weight of 1096.34 for the base form.

The label says the drug is believed to work much like natural somatostatin. It calls lanreotide an inhibitor of endocrine, neuroendocrine, exocrine and paracrine functions. Put simply, it turns down hormone and gut secretions across the body.

Somatostatin itself, and how it was found, is covered on our octreotide page, the older copy of the same hormone. Here we stay with what makes lanreotide its own drug.

Sources: Somatuline Depot label via openFDA, version 16

Why does lanreotide last for weeks?

Lanreotide lasts for weeks because it is thought to build its own store in the body. The label says the formulation is thought to form a drug depot when it mixes with body fluids. The drug then most likely leaves that depot by passive diffusion. It seeps into nearby tissue first, then into the blood. The label reports sustained release, with a half-life of 23 to 30 days.

A short ingredient list. Somatuline Depot holds lanreotide acetate, water and a little acetic acid to set the pH. It is a supersaturated solution, which the label describes as a white to pale yellow semi-solid. No polymer is listed. The CLARINET paper calls it an extended-release aqueous gel.

Tubes in a test tube. A 2003 lab study found that lanreotide molecules in water stack themselves into hollow nanotubes. The tubes were about 244 angstroms wide, with walls about 18 angstroms thick, packed in a six-sided pattern. That was physical chemistry, not a study in people. The paper did not show that these tubes explain how the depot releases the drug in the body, so we keep the two facts apart.

The scale of the change. Natural somatostatin lasts 1 to 3 minutes in blood. Immediate-release octreotide has a half-life of about 1.7 hours. Lanreotide from its depot is measured in weeks.

Sources: Somatuline Depot label via openFDA, version 16; Caplin and colleagues, CLARINET, NEJM 2014; Valery and colleagues, PNAS 2003; Sandostatin LAR Depot label via openFDA

Lanreotide vs octreotide: what is different?

Lanreotide and octreotide copy the same hormone, but they are built from different units and their long-acting forms last in different ways. Both labels call the drug a cyclic octapeptide; the table shows where they part ways.

Lanreotide and octreotide side by side, from their FDA labels and Drugs@FDA records.
TraitLanreotideOctreotide
What it copiesSomatostatinSomatostatin
Size and shapeRing of 8 units closed by a sulfur bondRing of 8 units, built from different parts
First unit3-(2-naphthyl)-D-alanine, an unusual blockD-phenylalanine (last unit is threoninol)
Molecular weight on the label1096.34 (base)1019.3
How the long-acting form lastsDrug, water and acetic acid only; thought to form its own depotDrug spread through tiny beads of a biodegradable polymer
First US approval30 August 2007 (Somatuline Depot)21 October 1988 (Sandostatin); long-acting form 25 November 1998
Contraindication on the labelPast allergy to lanreotideNone listed on the LAR label

Beads or a self-made store. In Sandostatin LAR Depot, octreotide is spread through microspheres made of a D,L-lactic and glycolic acid copolymer, beads the body breaks down over time. Lanreotide skips the beads.

Overlapping uses. Octreotide is also approved in the US for acromegaly. Its label also covers two tumor symptom uses: the severe flushing and diarrhea of carcinoid tumors once they spread, and heavy, watery diarrhea from tumors that release VIP.

What we cannot say. Our sources hold no head-to-head tumor trial of the two drugs, so this page does not call either one stronger. For the octreotide side in depth, from its receptor table to its capsule form, read the octreotide explainer.

Sources: Somatuline Depot label via openFDA, version 16; Sandostatin LAR Depot label via openFDA; Sandostatin label on DailyMed; Drugs@FDA lanreotide records via openFDA; Drugs@FDA record, NDA 021008

Which receptors does lanreotide bind?

Lanreotide binds somatostatin receptors 2 and 5 strongly and receptors 1, 3 and 4 more weakly. Somatostatin has five receptor types in all. The label says activity at types 2 and 5 is believed to be the main way lanreotide holds back growth hormone.

Growth hormone and IGF-1. Acromegaly is a disorder in which the body makes too much growth hormone. The label sets the treatment goal as bringing growth hormone and IGF-1, the growth factor it drives, back to normal. In one label study of 108 people with acromegaly, 63% of those on lanreotide had a drop of more than half in average growth hormone by week 4, against none on placebo. At the last check, 58% had a normal IGF-1 for their age, up from 8% at the start. For how growth hormone itself works, see our guide to growth hormone peptides.

The gut and the gallbladder. After meals, lanreotide lowers several digestive hormones: pancreatic polypeptide, gastrin and CCK. In healthy people it also holds back gallbladder squeezing and bile flow.

Insulin. In healthy people it reduces and delays insulin release after a meal. The label says this causes brief, mild glucose intolerance. Both the gallbladder and the insulin effects return in the warnings below.

Sources: Somatuline Depot label via openFDA, version 16; NIDDK, acromegaly

What is lanreotide used for?

The current US label lists three uses for lanreotide. They were added one at a time between 2007 and 2017.

  • Acromegaly (2007): long-term care when surgery or radiation did not work well enough, or is not an option.
  • GEP-NETs (2014): adults with neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery, are well or moderately differentiated, and are locally advanced or have spread. The goal is to improve progression-free survival. These tumors grow from hormone-making cells in the gut lining.
  • Carcinoid syndrome (2017): adults with this set of symptoms, caused by tumor hormones that stay in the body. Flushing of the face and neck and diarrhea are among the signs. Here the label says it reduces how often short-acting rescue medicine is needed.

Whether any of these fits a person is a call for their specialist. We report the label, nothing more.

Sources: Somatuline Depot label via openFDA, version 16; FDA approval letter, 30 August 2007; FDA approval letter, 16 December 2014; FDA approval letter, 15 September 2017; National Cancer Institute, GI neuroendocrine tumors (PDQ)

What did the CLARINET trial find?

CLARINET found that lanreotide delayed tumor growth or death, on average, in adults with certain advanced, nonfunctioning grade 1 or 2 neuroendocrine tumors. It was a randomized, double-blind, placebo-controlled trial run in many countries. It enrolled 204 people: 101 on lanreotide and 103 on placebo. Their tumors were advanced, did not release excess hormones, carried somatostatin receptors, and were grade 1 or 2 (Ki-67 under 10%). They started in the pancreas, midgut or hindgut, or their origin was unknown. Ipsen, the maker, funded the trial.

What it measured. The main measure was progression-free survival: the time until scans showed the tumor growing, judged by the RECIST 1.0 criteria, or until death. The label adds that a central, independent team read the scans.

  • Middle point: in the NEJM paper, half the placebo group had tumor growth or died by 18.0 months. On lanreotide, that middle point was never reached during the study. The FDA label's own analysis of the same trial puts the placebo figure at 16.6 months.
  • Relative risk: both sources give a hazard ratio of 0.47 (95% CI 0.30 to 0.73). That is roughly 53% lower risk of progression or death over the study period.
  • At two years: an estimated 65.1% on lanreotide were still free of progression, against 33.0% on placebo.
  • What did not change: quality of life and overall survival showed no significant difference between the groups.
  • Most common side effect tied to treatment: diarrhea, in 26% on lanreotide and 9% on placebo.

The extension. After the blinded phase, 88 patients stayed on or switched to lanreotide in an open-label extension. Counted from the first randomization, the middle point for those on lanreotide came at 32.8 months. Open-label data are weaker than the blinded trial. Every figure here is a group average, not a forecast for any one person.

Sources: Caplin and colleagues, CLARINET, NEJM 2014; Somatuline Depot label via openFDA, version 16; CLARINET open-label extension, 2016

How was lanreotide tested in carcinoid syndrome?

Lanreotide was tested in carcinoid syndrome in a 16-week, double-blind trial of 115 adults. The label calls it Study 4, and the published paper names it ELECT. People on lanreotide needed rescue octreotide on 34% of days, against 49% on placebo (p=0.02). That gap is 15 percentage points, not a 15% relative drop. The published paper reports 33.7% against 48.5%.

Flushing and diarrhea counts were lower on lanreotide, but the difference was not statistically significant.

Two copies, one trial. In ELECT, short-acting octreotide was the rescue medicine everyone could use. So the two drugs ran side by side in that study. They were not compared head to head.

Sources: Somatuline Depot label via openFDA, version 16; Vinik and colleagues, ELECT, 2016

What are the side effects of lanreotide?

Most of the label warnings for lanreotide follow from the hormones it slows down.

  • Gallstones: it may slow the gallbladder and lead to gallstones. Reports since approval include an inflamed gallbladder, inflamed bile ducts and pancreatitis, and some people needed their gallbladder removed.
  • Blood sugar: like somatostatin, it holds back both insulin and glucagon. Blood sugar can run too low or too high.
  • Heart rate: in three pooled acromegaly heart studies, 5.5% (12 of 217) had sinus bradycardia, a slow regular rhythm, and 2.8% had bradycardia.
  • Thyroid: thyroid function dipped slightly in people with acromegaly. Clinical hypothyroidism was rare, under 1%.
  • Fat absorption: somatostatin drugs can slow pancreas enzymes and bile acids, which can lead to fatty stools.
  • Allergy: lanreotide is ruled out for anyone with a past allergy to it. Angioedema and anaphylaxis have been reported.

Common side effects. In acromegaly (above 5%): diarrhea, gallstones, belly pain, nausea and reactions where the drug went in. In GEP-NETs (above 10%): belly pain, muscle and bone pain, vomiting, headache, reactions where the drug went in, high blood sugar, high blood pressure and gallstones. In carcinoid syndrome the label adds headache, dizziness and muscle spasm.

Animal data. In lifetime studies in mice and rats, tumors of fibrous tissue formed where the drug went in. In mice this happened at the highest exposure tested, and in rats at exposures below those in human treatment. The label says it may not be clinically relevant to people. Lanreotide did not damage genes in lab tests. Only a treating doctor can weigh these risks for one person.

Sources: Somatuline Depot label via openFDA, version 16

Is lanreotide still FDA approved?

Yes. On 20 November 2026, Drugs@FDA listed Somatuline Depot (NDA 022074, Ipsen) as a prescription drug, approved for acromegaly, GEP-NETs and carcinoid syndrome. Its current DailyMed label is version 16, published 17 October 2024, and no newer version had appeared by 19 November 2026.

Lanreotide approvals in the US, from FDA letters and Drugs@FDA, checked 20 November 2026.
DateWhat happened
30 August 2007Somatuline Depot (Ipsen) first approved, for long-term acromegaly care when surgery or radiation fell short or could not be used. A new molecular entity.
16 December 2014Added: adults with certain advanced GEP-NETs, to improve progression-free survival.
15 September 2017Added: adults with carcinoid syndrome, to cut how often short-acting rescue medicine is needed.
17 December 2021A second lanreotide product (InvaGen, NDA 215395) approved through the 505(b)(2) route. Now listed Discontinued.
21 May 2024A generic from InvaGen (ANDA 217193) approved. Now listed Discontinued.
18 September 2026A generic from Amneal (ANDA 218217) approved, listed as Prescription. It was not the first generic.

A mixed picture for the older products. DailyMed still carries labels tied to the two InvaGen applications, from Cipla and Exelan. So whether each product can be bought today is not something we could confirm. A Prescription listing shows approval, not stock.

We check status lines like these against FDA records, as our medical review policy describes.

Sources: Drugs@FDA lanreotide records via openFDA; Somatuline Depot label history on DailyMed; FDA approval letter, 30 August 2007; FDA approval letter, 16 December 2014; FDA approval letter, 15 September 2017; FDA approval letter, NDA 215395, 17 December 2021

What else do people ask about lanreotide?

What is lanreotide?+

Lanreotide is a prescription drug that mimics somatostatin, a natural hormone that slows the release of growth hormone and many gut hormones. Its FDA label calls it a synthetic cyclical octapeptide: a ring of 8 units. The brand is Somatuline Depot, made by Ipsen and first approved in the US on 30 August 2007.

What is lanreotide used for?+

The US label lists three uses. One is long-term care of acromegaly when surgery or radiation did not work well enough or is not an option. Two is adults with certain advanced gut and pancreas neuroendocrine tumors (GEP-NETs), to improve progression-free survival. Three is adults with carcinoid syndrome, to reduce the need for short-acting rescue medicine.

How does lanreotide work?+

It binds somatostatin receptors, gripping types 2 and 5 hardest and types 1, 3 and 4 more weakly. The label says its action at types 2 and 5 is believed to be the main way it lowers growth hormone. It also slows several gut hormones, gallbladder squeezing and insulin release after meals.

Why does lanreotide last so long?+

The label says the formulation is thought to form a depot when it meets body fluids, and the drug most likely seeps out slowly into nearby tissue, then the blood. Its half-life is 23 to 30 days. Natural somatostatin lasts 1 to 3 minutes in blood.

What is the difference between lanreotide and octreotide?+

Both copy somatostatin and both are 8-unit rings, but they are built from different units. Their long-acting forms last in different ways: octreotide LAR sits in tiny polymer beads, while lanreotide has no polymer and is thought to form its own depot. No head-to-head tumor trial was found in our sources, so this page does not rank one above the other.

Is lanreotide chemotherapy?+

Its label calls it a somatostatin analog, a hormone copy, and does not describe it as a drug that kills cells. For GEP-NETs, its approved role is to improve progression-free survival. In the CLARINET trial it delayed tumor growth or death on average, with no clear difference in overall survival.

What is Somatuline Depot?+

Somatuline Depot is the Ipsen brand of lanreotide. Drugs@FDA classes its 2007 approval as a new molecular entity and listed it as a prescription drug when we checked on 20 November 2026. Its current DailyMed label is version 16, published 17 October 2024.

Is there a generic lanreotide?+

Yes. Drugs@FDA lists an Amneal generic approved on 18 September 2026 as a prescription drug. An earlier InvaGen generic from May 2024, and a separate InvaGen lanreotide product from December 2021, are now listed as discontinued. Drugs@FDA status shows approval, not stock in any one place.

What are the side effects of lanreotide?+

Label warnings cover gallstones, blood sugar that runs too low or too high, a slower heart rate, slightly lower thyroid function and fatty stools. In acromegaly the most common side effects were diarrhea, gallstones, belly pain, nausea and reactions where the drug went in. In CLARINET, diarrhea tied to treatment hit 26% on lanreotide and 9% on placebo.

Is lanreotide a peptide?+

Yes. Peptides are short chains of amino acids, and lanreotide is a chain of 8 joined into a ring. Octreotide is another lab-made somatostatin copy, built from different units.

Sources: Somatuline Depot label via openFDA, version 16; Drugs@FDA lanreotide records via openFDA; Somatuline Depot label history on DailyMed; Sandostatin LAR Depot label via openFDA; Caplin and colleagues, CLARINET, NEJM 2014

What did we learn about lanreotide?

In short, lanreotide turns a hormone that lasts minutes into a drug that lasts weeks, with no polymer beads, and its tumor trial showed a delay in growth on average rather than longer survival.

Molecule Mechanics makes short animated lessons on how molecules work, each with its sources listed. It explains; it never recommends a treatment. Other drugs in the series include octreotide, oral semaglutide and, where the series began, how tirzepatide works.

Spotted a wrong figure in this lanreotide explainer? Use our corrections policy to report it.

Sources: Somatuline Depot label via openFDA, version 16; Caplin and colleagues, CLARINET, NEJM 2014

Education only, not medical advice. This page is built from FDA labels, FDA approval records and published trials of lanreotide (Somatuline Depot). Any decision about a prescription drug belongs to the patient and their own doctor.

Sources

  1. 1.SOMATULINE DEPOT (lanreotide) FDA prescribing information, Ipsen, label version 16 (effective 11 October 2024), read through openFDA on 20 November 2026: the primary record for the three uses, the structure, the depot, the half-life, the receptor profile, the acromegaly and carcinoid syndrome trials and every warning on this page. Parts used: 1 (uses); 4 (contraindication); 5.1 to 5.4 (gallstones, blood sugar, heart rate, thyroid and fat absorption); 6 (common side effects); 11 (synthetic cyclical octapeptide, chemical name, 1096.34 base, ingredients, semi-solid form); 12.1 to 12.3 (mechanism, SSTR binding, gut and gallbladder effects, insulin, depot and 23 to 30 day half-life); 13.1 (rodent findings); 14 (Study 1 acromegaly, Study 3 GEP-NETs, Study 4 carcinoid syndrome).
  2. 2.DailyMed, Somatuline Depot label history (set id 6e4a41fd): version 16, published 17 October 2024; no newer version found on 19 November 2026.
  3. 3.SANDOSTATIN LAR DEPOT (octreotide) FDA prescribing information, Novartis, label dated 22 December 2025, via openFDA: octreotide as a cyclic octapeptide (1019.3), its sequence from D-phenylalanine to threoninol, the microspheres of a biodegradable D,L-lactic and glycolic acid copolymer, and the 1.7 hour half-life of immediate-release octreotide against 1 to 3 minutes for somatostatin.
  4. 4.SANDOSTATIN (octreotide) label on DailyMed: the three US uses of octreotide (acromegaly, carcinoid tumor diarrhea and flushing, VIPoma diarrhea).
  5. 5.Drugs@FDA through openFDA, every lanreotide application, read 20 November 2026: NDA 022074 (Ipsen, original approval 30 August 2007, Type 1 new molecular entity, Prescription); NDA 215395 (InvaGen, approved 17 December 2021, Discontinued); ANDA 217193 (InvaGen, approved 21 May 2024, Discontinued); ANDA 218217 (Amneal, approved 18 September 2026, Prescription).
  6. 6.Drugs@FDA through openFDA, NDA 021008 (Sandostatin LAR Depot, Novartis): original approval 25 November 1998, listed as Prescription. Sandostatin injection, NDA 019667, first approved 21 October 1988.
  7. 7.FDA approval letter for NDA 022074, 30 August 2007: long-term treatment of acromegaly in patients who had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. Addressed to Biomeasure, US agent for Beaufour Ipsen Pharma.
  8. 8.FDA approval letter for NDA 022074 supplement 11, 16 December 2014: new indication for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs, to improve progression-free survival.
  9. 9.FDA approval letter for NDA 022074 supplement 17, 15 September 2017: new indication for adults with carcinoid syndrome, to reduce the frequency of short-acting somatostatin analog rescue therapy.
  10. 10.FDA approval letter for NDA 215395 (Lanreotide Injection, InvaGen), 17 December 2021, a 505(b)(2) application for acromegaly and GEP-NETs.
  11. 11.Valery C, Paternostre M, Robert B, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. PNAS, 2003, PMID 12930900. Lab chemistry in water: hollow nanotubes about 244 angstroms wide, walls about 18 angstroms, hexagonal packing, built from beta-sheets. Not a human study, and it does not test the depot in the body.
  12. 12.Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET). New England Journal of Medicine, 2014, PMID 25014687, NCT00353496. Randomized, double-blind, placebo-controlled, multinational; 204 patients (101 and 103); progression-free survival by RECIST 1.0 or death; median not reached against 18.0 months, hazard ratio 0.47 (95% CI 0.30 to 0.73); 65.1% against 33.0% at 24 months; no difference in quality of life or overall survival; diarrhea 26% against 9%. Funded by Ipsen.
  13. 13.Caplin ME, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-Related Cancer, 2016, PMID 26743120. 88 patients; median progression-free survival on lanreotide 32.8 months, counted from the original randomization.
  14. 14.Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT). Endocrine Practice, 2016, PMID 27214300. Short-acting octreotide was the rescue medicine; rescue on 33.7% against 48.5% of days.
  15. 15.NIDDK (US National Institutes of Health), Acromegaly page, read 20 November 2026: a disorder that occurs when the body makes too much growth hormone.
  16. 16.National Cancer Institute, Gastrointestinal Neuroendocrine Tumors Treatment (PDQ), patient version, read 20 November 2026: tumors that form from hormone-making neuroendocrine cells in the gut lining, and carcinoid syndrome from hormones that stay in the body, with flushing and diarrhea among the signs.